|
| Overall Recruitment Status: Active, currently enrolling |
| |
| Official Title |
| Phase 3, Open-Label, Randomized, Study Comparing Gedatolisib Combined With Fulvestrant & With or Without Palbociclib to Standard-of-Care Therapies in Patients With HR-Positive, HER2-Negative Advanced Breast Cancer Previously Treated With a CDK4/6 Inhibitor in Combination w/Non-SteroidalAromatase Inhibitor Therapy
|
| |
| Region |
Sponsors |
| Hawaii |
|
| |
| Acronym |
NCT No. |
|
NCT05501886 |
| |
| Study Type |
Phase |
| Clinical Trial |
|
| |
| Purpose |
| The purpose of this study is to evaluate the safety and effectiveness of gedatolisib at treating cancer when combined with other cancer drugs, compared to the standard-of-care for people with breast cancer. |
| |
| Detailed Description |
| This is a Phase 3, open-label, randomized clinical trial evaluating the efficacy and safety of gedatolisib plus fulvestrant with or without palbociclib for the treatment of patients with advanced (inoperable) or metastatic Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) breast cancer following progression on or after CDK4/6 and aromatase inhibitor therapy. Gedatolisib is an intravenously administered pan-PI3K/mTOR inhibitor. Palbociclib is a CDK4/6 inhibitor. Fulvestrant is a selective estrogen receptor degrader (SERD). Subjects will be assessed for PIK3CA status and then randomized to treatment arms according to their confirmed PIK3CA mutation status. |
| |
| |
| |
- 1. Histologically or cytologically confirmed diagnosis of metastatic or locally advanced breast cancer
Adult females, pre- and/or post-menopausal, and adult males. Pre-menopausal (and peri-menopausal) women can be enrolled if amenable to treatment with an LHRH agonist. Patients are to
have commenced concomitant treatment with LHRH agonist prior to or on Cycle 1, Day 1 and must
be willing to continue on it for the duration of the study.
2. Negative pregnancy test for women of childbearing potential. Female subjects of childbearing
potential must use an effective and/or acceptable contraceptive method from screening until 1 year
after the last dose of study treatment
3. Confirmed diagnosis of estrogen receptor positive and/or progesterone receptor positive, as per
American Society of Clinical Oncology/College of American Pathologists (ASCO-CAP) guidelines
(2020), based on most recent tumor biopsy utilizing an assay consistent with local standards
4. Documented HER2 immunohistochemistry (IHC) negative as per ASCO-CAP 2018 guidance
5. Adequate archival or fresh tumor tissue for the analysis of PIK3CA mutational status
|
|
| |
- 1. History of malignancies other than adequately treated non-melanoma skin cancer, curatively treated in situ cancer of the cervix, or other solid tumors curatively treated with no evidence of disease for =3 years
2. Prior treatment with a phosphoinositide 3-kinase (PI3K) inhibitor, a protein kinase B (Akt) inhibitor, or
a mechanistic target of rapamycin (mTOR) inhibitor
3. Prior treatment with chemotherapy and antibody drug conjugates for advanced disease is not
permitted (prior adjuvant or neoadjuvant chemotherapy is permitted)
4. More than 2 lines of prior endocrine therapy treatment
5. Bone only disease that is only blastic with no soft tissue component
|
|
| |
|
|
| |
|